Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(5):649–655. doi: 10.1054/bjoc.2001.2010

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

X Pivot 1, E Raymond 2, B Laguerre 3, M Degardin 4, L Cals 5, J P Armand 2, J L Lefebvre 4, D Gedouin 3, V Ripoche 6, L Kayitalire 6, C Niyikiza 7, R Johnson 7, J Latz, M Schneider 1
PMCID: PMC2364119  PMID: 11531245

Abstract

This phase II study determined response rate of patients with locally advanced or metastatic head and neck cancer treated with pemetrexed disodium, a new multitargeted antifolate that inhibits thymidylate synthase, dihydrofolate reductase and glycinamide ribonucleotide formyl transferase. 35 patients with local or metastatic relapse of squamous cell carcinoma of the head and neck (31 male, 4 female; median age 53 years) were treated with pemetrexed 500 mg m2 administered as a 10-minute infusion on day 1 of a 21-day cycle. Patients received 1 to 8 cycles of therapy. 9 patients (26.5%) had an objective response, with a median response duration of 5.6 months (range 2.9–20 months). 15 (44.1%) had stable disease, and 8 (23.5%) had progressive disease. 2 patients were not assessable for response. Median overall survival was 6.4 months (range 0.7–28.1 months; 95% CI: 3.9–7.7 months). 24 patients (68.6%) experienced grade 3/4 neutropenia, with febrile neutropenia in 4 (11.4%). Grade 3/4 anaemia and thrombocytopenia occurred in 11 (34.3%) and 6 (17.1%) patients, respectively. The most frequent non-haematological toxicity was grade 3/4 mucositis (17.1%; 6 patients). In conclusion, pemetrexed is active in squamous cell carcinoma of the head and neck. Although substantial haematological toxicities were experienced by patients, subsequent studies have shown that these toxicities can be proactively managed by folic acid and vitamin B12 supplementation. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: LY231514, pemetrexed disodium, ALIMTA®, multitargeted antifolate, head and neck squamous cell carcinoma, chemotherapy

Full Text

The Full Text of this article is available as a PDF (85.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alati T., Worzalla J. F., Shih C., Bewley J. R., Lewis S., Moran R. G., Grindey G. B. Augmentation of the therapeutic activity of lometrexol -(6-R)5,10-dideazatetrahydrofolate- by oral folic acid. Cancer Res. 1996 May 15;56(10):2331–2335. [PubMed] [Google Scholar]
  2. Calvert A. H., Walling J. M. Clinical studies with MTA. Br J Cancer. 1998;78 (Suppl 3):35–40. doi: 10.1038/bjc.1998.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chen V. J., Bewley J. R., Andis S. L., Schultz R. M., Iversen P. W., Shih C., Mendelsohn L. G., Seitz D. E., Tonkinson J. L. Cellular pharmacology of MTA: a correlation of MTA-induced cellular toxicity and in vitro enzyme inhibition with its effect on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells. Semin Oncol. 1999 Apr;26(2 Suppl 6):48–54. [PubMed] [Google Scholar]
  4. Clavel M., Vermorken J. B., Cognetti F., Cappelaere P., de Mulder P. H., Schornagel J. H., Tueni E. A., Verweij J., Wildiers J., Clerico M. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994 Jul;5(6):521–526. doi: 10.1093/oxfordjournals.annonc.a058906. [DOI] [PubMed] [Google Scholar]
  5. Dimery I. W., Hong W. K. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst. 1993 Jan 20;85(2):95–111. doi: 10.1093/jnci/85.2.95. [DOI] [PubMed] [Google Scholar]
  6. Forastiere A. A., Metch B., Schuller D. E., Ensley J. F., Hutchins L. F., Triozzi P., Kish J. A., McClure S., VonFeldt E., Williamson S. K. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992 Aug;10(8):1245–1251. doi: 10.1200/JCO.1992.10.8.1245. [DOI] [PubMed] [Google Scholar]
  7. Jacobs C., Meyers F., Hendrickson C., Kohler M., Carter S. A randomized phase III study of cisplatin with or without methotrexate for recurrent squamous cell carcinoma of the head and neck. A Northern California Oncology Group study. Cancer. 1983 Nov 1;52(9):1563–1569. doi: 10.1002/1097-0142(19831101)52:9<1563::aid-cncr2820520904>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  8. Landis S. H., Murray T., Bolden S., Wingo P. A. Cancer statistics, 1999. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1. doi: 10.3322/canjclin.49.1.8. [DOI] [PubMed] [Google Scholar]
  9. Mendelsohn L. G., Gates S. B., Habeck L. L., Shackelford K. A., Worzalla J., Shih C., Grindey G. B. The role of dietary folate in modulation of folate receptor expression, folylpolyglutamate synthetase activity and the efficacy and toxicity of lometrexol. Adv Enzyme Regul. 1996;36:365–381. doi: 10.1016/0065-2571(96)00001-5. [DOI] [PubMed] [Google Scholar]
  10. Morgan S. L., Baggott J. E., Vaughn W. H., Young P. K., Austin J. V., Krumdieck C. L., Alarcón G. S. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 1990 Jan;33(1):9–18. doi: 10.1002/art.1780330102. [DOI] [PubMed] [Google Scholar]
  11. O'Dwyer P. J., Nelson K., Thornton D. E. Overview of phase II trials of MTA in solid tumors. Semin Oncol. 1999 Apr;26(2 Suppl 6):99–104. [PubMed] [Google Scholar]
  12. Postmus P. E., Green M. R. Overview of MTA in the treatment of non-small cell lung cancer. Semin Oncol. 1999 Feb;26(1 Suppl 4):31–36. [PubMed] [Google Scholar]
  13. Recondo G., Armand J. P., Tellez-Bernal E., Domenge C., Belehradek M., De Vathaire F., Wibault P., Richard J. M., Cvitkovic E. Recurrent and/or metastatic head and neck squamous cell carcinoma: a clinical, univariate and multivariate analysis of response and survival with cisplatin-based chemotherapy. Laryngoscope. 1991 May;101(5):494–501. doi: 10.1288/00005537-199105000-00009. [DOI] [PubMed] [Google Scholar]
  14. Rinaldi D. A., Kuhn J. G., Burris H. A., Dorr F. A., Rodriguez G., Eckhardt S. G., Jones S., Woodworth J. R., Baker S., Langley C. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol. 1999;44(5):372–380. doi: 10.1007/s002800050992. [DOI] [PubMed] [Google Scholar]
  15. Rusthoven J. J., Eisenhauer E., Butts C., Gregg R., Dancey J., Fisher B., Iglesias J. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999 Apr;17(4):1194–1194. doi: 10.1200/JCO.1999.17.4.1194. [DOI] [PubMed] [Google Scholar]
  16. Schornagel J. H., Verweij J., de Mulder P. H., Cognetti F., Vermorken J. B., Cappelaere P., Armand J. P., Wildiers J., de Graeff A., Clavel M. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995 Jul;13(7):1649–1655. doi: 10.1200/JCO.1995.13.7.1649. [DOI] [PubMed] [Google Scholar]
  17. Shih C., Chen V. J., Gossett L. S., Gates S. B., MacKellar W. C., Habeck L. L., Shackelford K. A., Mendelsohn L. G., Soose D. J., Patel V. F. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116–1123. [PubMed] [Google Scholar]
  18. Smith G. K., Amyx H., Boytos C. M., Duch D. S., Ferone R., Wilson H. R. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res. 1995 Dec 15;55(24):6117–6125. [PubMed] [Google Scholar]
  19. Vogl S. E., Schoenfeld D. A., Kaplan B. H., Lerner H. J., Engstrom P. F., Horton J. A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer. 1985 Aug 1;56(3):432–442. doi: 10.1002/1097-0142(19850801)56:3<432::aid-cncr2820560304>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  20. Vokes E. E., Weichselbaum R. R., Lippman S. M., Hong W. K. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184–194. doi: 10.1056/NEJM199301213280306. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES